SELLAS Life Sciences Group, Inc. - Common Stock (NQ:SLS)

4.860 +0.350 (+7.76%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2026 Add to My Watchlist

Price and Volume

Volume	4,080,091
Open	4.790
Bid (Size)	4.840 (1,200)
Ask (Size)	4.860 (2,000)
Prev. Close	4.510
Today's Range	4.715 - 4.920
52wk Range	0.9516 - 6.140
Shares Outstanding	15,873,941
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum ↗

March 18, 2026

Investors are also watching the late-stage GPS immunotherapy trial, which is nearing final analysis with 72 of 80 survival events recorded.

Via Stocktwits

SLS Stock In Spotlight: First AML Patient Enrolled In Phase 2 Leukemia Trial ↗

March 12, 2026

The study aims to evaluate SLS009’s effectiveness in a molecularly defined cohort of frontline leukemia patients, enrolling approximately 80 patients across two high-priority groups.

Via Stocktwits

Performance

YTD	+11.7%	+11.7%
1 Month	-18.5%	-18.5%
3 Month	+18.5%	+18.5%
6 Month	+155.8%	+155.8%
1 Year	+367.3%	+367.3%

More News

SLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Fail ↗

March 09, 2026

Via Stocktwits

Dow, S&P 500, Nasdaq Futures Dip After Wall Street Rebound: Why SLS, ZVRA, RLMD, USO, CASY Are Trending After-Hours ↗

March 09, 2026

Via Stocktwits

SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off? ↗

January 09, 2026

Via Stocktwits

SLS Stock Falls Premarket: CEO Touts GPS Leukemia Strategy, But Investors Stay Cautious As AML Trial Nears Readout ↗

March 09, 2026

Via Stocktwits

SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout ↗

March 06, 2026

Via Stocktwits

SLS Stock’s Red-Hot Streak Draws Rising Short Bets — Retail Traders Are Now Betting On A Big Pharma Buyout ↗

March 05, 2026

Via Stocktwits

SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside ↗

March 04, 2026

Via Stocktwits

SLS Stokes Retail Anticipation For Breakout Rally — What’s Driving The Interest? ↗

February 27, 2026

Via Stocktwits

Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% ↗

February 23, 2026

Via Stocktwits

SLS Stock In Spotlight On EU Expansion For Cancer Therapy – Retail Says Potential Catalyst For Buyout ↗

January 14, 2026

Via Stocktwits

The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech

January 08, 2026

From Equity Insider

Via GlobeNewswire

Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗

January 06, 2026

Via Chartmill

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

January 06, 2026

Via Chartmill

Nasdaq, S&P 500 Futures Edge Lower Despite CES-Driven AI Optimism: Why NVDA, TSLA, AMD, AEVA, OS Are On Traders' Radar Today ↗

January 06, 2026

Via Stocktwits

SLS Stock Breaches $5 Level After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B ↗

January 05, 2026

Via Stocktwits

Why Is SLS Stock Drawing Significant Investor Attention Today? ↗

December 31, 2025

Via Stocktwits

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

Via MarketMinute

SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study ↗

December 29, 2025

Via Stocktwits

SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About? ↗

December 24, 2025

Via Stocktwits

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

December 24, 2025

From Equity Insider

Via GlobeNewswire

These stocks are gapping in today's session ↗

December 23, 2025

Via Chartmill

SELLAS Life Sciences Stock Has Doubled This Year – Here’s Why Retail Investors Are Bullish ↗

December 17, 2025

Via Stocktwits

SELLAS Life Sciences Draws Retail Buzz On SLS009 Trial Momentum – Stock Soars In Pre-Market ↗

December 08, 2025

Via Stocktwits

Frequently Asked Questions

Is SELLAS Life Sciences Group, Inc. - Common Stock publicly traded?

Yes, SELLAS Life Sciences Group, Inc. - Common Stock is publicly traded.

What exchange does SELLAS Life Sciences Group, Inc. - Common Stock trade on?

SELLAS Life Sciences Group, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for SELLAS Life Sciences Group, Inc. - Common Stock?

The ticker symbol for SELLAS Life Sciences Group, Inc. - Common Stock is SLS on the Nasdaq Stock Market

What is the current price of SELLAS Life Sciences Group, Inc. - Common Stock?

The current price of SELLAS Life Sciences Group, Inc. - Common Stock is 4.860

When was SELLAS Life Sciences Group, Inc. - Common Stock last traded?

The last trade of SELLAS Life Sciences Group, Inc. - Common Stock was at 04/08/26 04:00 PM ET

What is the market capitalization of SELLAS Life Sciences Group, Inc. - Common Stock?

The market capitalization of SELLAS Life Sciences Group, Inc. - Common Stock is 77.15M

How many shares of SELLAS Life Sciences Group, Inc. - Common Stock are outstanding?

SELLAS Life Sciences Group, Inc. - Common Stock has 77M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.